Monsanto Collaborates with Second Genome to use Microbiome Technology Platform to Accelerate Protein Discovery

September 6, 2016, St. Louis, MO and South San Francisco, CA

Microbial genome analysis using big data science, bioinformatics and machine learning expected to drive discovery of microbiome-based solutions that can help farmers better manage on-farm challenges

Read More

Second Genome Appoints Glenn Nedwin, Ph.D., as Chief Executive Officer

July 13, 2016, South San Francisco, CA

Second Genome, Inc., a privately-held biopharmaceutical company developing novel medicines through innovative microbiome science, today announced the appointment of Glenn Nedwin, Ph.D., as chief executive officer, president and member of the company’s board of directors. Dr. Nedwin joins Second Genome as the company accelerates the translation of its microbiome discoveries into a pipeline of clinical opportunities.

Read More

Second Genome Secures $42.6 Million in Series B Financing Led by Pfizer Venture Investments and Roche Venture Fund

April 20, 2016, South San Francisco, CA

Second Genome, Inc., a privately-held biopharmaceutical company developing novel medicines through innovative microbiome science, today announced that it has closed an oversubscribed Series B investment round with $42.6 million in financing. The round was co-led by Pfizer Venture Investments and Roche Venture Fund, and brings the combined total investment in the company to $59 million.

Read More

Second Genome Announces Inflammatory Bowel Disease Research Alliance with the APC Microbiome Institute at University College Cork

April 27, 2015, South San Francisco, CA

Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, has entered into an alliance with the Alimentary Pharmabiotic Centre (APC) Microbiome Institute at University College Cork (UCC), Ireland, to advance the development of therapies that prevent and treat inflammatory bowel disease (IBD). Scientists from both groups will partner to explore the role of the microbiome in IBD by analyzing data from patients to identify new opportunities for therapeutic intervention.

Read More

Second Genome Advances Lead Microbiome Drug Development Program in Phase I Clinical Trial as a Treatment for Inflammatory Bowel Disease

January 12, 2015, South San Francisco, CA

Second Genome, Inc., a pioneer in the development of novel medicines through innovative microbiome science, announced today that the company is advancing its lead drug candidate, SGM-1019, into a Phase I multiple-ascending dose clinical trial for the treatment of inflammatory bowel disease. SGM-1019 inhibits a target that Second Genome researchers discovered to be a key driver of inflammatory bowel disease when modulated by changes in the microbiome.

Read More

Second Genome and Mayo Clinic Enter Collaboration to Develop Microbiome Therapeutics in Multiple Diseases

October 7, 2014, South San Francisco, CA

Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, has entered into an extensive partnership with the Mayo Clinic Center for Individualized Medicine to support the development of therapeutic products for multiple disease indications, starting with inflammatory bowel disease, metabolic disorders, and colorectal cancer.

Read More

Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Scientific Officer

September 9, 2014, South San Francisco, CA

Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, announced today that it has appointed Karim Dabbagh, Ph.D., as the company’s Chief Scientific Officer. In this new position, Dr. Dabbagh will be responsible for the company’s drug pipeline, fueled by Second Genome’s novel discovery platform for identifying and validating microbiome-mediated drug targets and therapeutics.

Read More

Second Genome Enters Into Agreement with Pfizer Inc. on Microbiome Research Initiative in Obesity

May 2, 2014, South San Francisco, CA

Second Genome announced today that it has entered into an agreement with Pfizer Inc. to conduct extensive microbiome research in a large observational study aimed at gaining new insights into obesity and metabolic disease. The goal of the study is to evaluate numerous clinical factors and the microbiome in a select cohort of approximately 900 individuals with varying metabolic phenotypes, in order to better understand the inter-relationship between the microbiome, obesity and metabolic disorders.

Read More